LeMaitre Vascular (NASDAQ:LMAT) Given New $110.00 Price Target at Lake Street Capital

LeMaitre Vascular (NASDAQ:LMAT) had its price objective increased by Lake Street Capital from $105.00 to $110.00 in a research note published on Friday,Benzinga reports. Lake Street Capital currently has a buy rating on the medical instruments supplier’s stock.

A number of other research firms have also recently issued reports on LMAT. StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Oppenheimer cut LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday. Barrington Research cut LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday. Finally, Wells Fargo & Company started coverage on LeMaitre Vascular in a report on Thursday, February 13th. They set an “equal weight” rating and a $95.00 price objective for the company. Five investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, LeMaitre Vascular currently has an average rating of “Moderate Buy” and an average price target of $95.25.

LeMaitre Vascular Price Performance

LMAT opened at $91.85 on Friday. The company has a market capitalization of $2.07 billion, a P/E ratio of 50.19, a P/E/G ratio of 2.22 and a beta of 0.96. The firm’s fifty day moving average price is $96.90 and its two-hundred day moving average price is $94.66. LeMaitre Vascular has a fifty-two week low of $62.39 and a fifty-two week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.49. The company had revenue of $55.81 million during the quarter, compared to analysts’ expectations of $55.99 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. On average, equities research analysts expect that LeMaitre Vascular will post 1.94 EPS for the current fiscal year.

Hedge Funds Weigh In On LeMaitre Vascular

A number of large investors have recently bought and sold shares of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in LeMaitre Vascular by 1.3% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 35,737 shares of the medical instruments supplier’s stock worth $3,293,000 after acquiring an additional 470 shares during the last quarter. Snowden Capital Advisors LLC raised its stake in shares of LeMaitre Vascular by 10.8% during the 4th quarter. Snowden Capital Advisors LLC now owns 7,733 shares of the medical instruments supplier’s stock worth $713,000 after purchasing an additional 751 shares in the last quarter. Nicholas Investment Partners LP raised its stake in shares of LeMaitre Vascular by 4.3% during the 4th quarter. Nicholas Investment Partners LP now owns 51,597 shares of the medical instruments supplier’s stock worth $4,754,000 after purchasing an additional 2,116 shares in the last quarter. Occudo Quantitative Strategies LP raised its stake in shares of LeMaitre Vascular by 20.0% during the 4th quarter. Occudo Quantitative Strategies LP now owns 3,413 shares of the medical instruments supplier’s stock worth $314,000 after purchasing an additional 569 shares in the last quarter. Finally, Millennium Management LLC raised its stake in shares of LeMaitre Vascular by 96.8% during the 4th quarter. Millennium Management LLC now owns 96,081 shares of the medical instruments supplier’s stock worth $8,853,000 after purchasing an additional 47,250 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.